Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model

• Published in: The European respiratory journal Vol. 29; no. 5; pp. 965 - 968
• Main Authors: Imamura, Y, Yanagihara, K, Fukuda, Y, Kaneko, Y, Seki, M, Izumikawa, K, Miyazaki, Y, Hirakata, Y, Sawa, T, Wiener-Kronish, J. P, Kohno, S
• Format: Journal Article
• Language: English
• Published: Leeds Eur Respiratory Soc 01-05-2007; Maney
• Subjects: Animals; Antibodies, Bacterial - metabolism; Antibodies, Bacterial - therapeutic use; Antigens, Bacterial - immunology; Bacterial Toxins - immunology; Biological and medical sciences; Bronchoalveolar Lavage Fluid - chemistry; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; General aspects; Human infectious diseases. Experimental studies and models; Immunoglobulin Fab Fragments - metabolism; Immunoglobulin Fab Fragments - therapeutic use; Immunoglobulin G - metabolism; Immunoglobulin G - therapeutic use; Infectious diseases; Male; Medical sciences; Mice; Pneumology; Pore Forming Cytotoxic Proteins; Pseudomonas aeruginosa - immunology; Pseudomonas aeruginosa - pathogenicity; Pseudomonas Infections - immunology; Pseudomonas Infections - microbiology; Pseudomonas Infections - therapy; Respiratory Tract Infections - immunology; Respiratory Tract Infections - microbiology; Respiratory Tract Infections - therapy; Pseudomonadales; Nosocomial infection; Antibody; Secretion; Rodentia; Infection; Vertebrata; Chronic; Mammalia; Mouse; Animal; type III secretion system; Bacteriosis; Bacteria; Pseudomonadaceae; Pseudomonas aeruginosa; Models; Anti-PcrV antibody; chronic airway infection; Pneumology
• ISSN: 0903-1936; 1399-3003
• DOI: 10.1183/09031936.00147406

Pseudomonas aeruginosa is one of the most important pathogens in patients with chronic airway conditions, such as cystic fibrosis and diffuse panbronchiolitis. Type III secretion system-mediated virulence factors contribute to the lung damage in chronic P. aeruginosa infection. The effects of the anti-PcrV immunoglobulin (Ig)G, which blocks the type III secretion system, were evaluated in a mouse model of chronic P. aeruginosa infection. On bacteriological examination, anti-PcrV IgG showed no bactericidal effects. On bronchoalveolar lavage fluid (BALF) analysis, total cell number and neutrophil ratios in the anti-PcrV IgG-treated groups were lower than those in the control group. In addition, macrophage inflammatory protein-2, tumour necrosis factor-alpha, and interleukin-beta concentrations in BALF were lower in the anti-PcrV IgG-treated groups when compared with controls. Plasma anti-PcrV IgG titre was elevated after administration of anti-PcrV IgG. Although plasma titre decreased gradually, a significant concentration was maintained during the experimental period. These data suggest that anti-PcrV immunoglobulin G reduces the inflammatory reaction caused by chronic Pseudomonas aeruginosa respiratory infection and may be useful in treating respiratory diseases.